Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept

被引：0
|
作者：
Thorne, J. Carter [1 ]
Keystone, Edward C. [2 ]
Pope, Janet E. [3 ]
Poulin-Costello, Melanie [4 ]
Phan-Chronis, Krystene [4 ]
Haraoui, Boulos [5 ]
机构：
[1] Southlake Reg Hlth Ctr, Newmarket, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] St Joseph Hlth Care, London, ON, Canada
[4] Amgen Canada Inc, Mississauga, ON, Canada
[5] Inst Rhumatol Montreal IRM, Montreal, PQ, Canada
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
492
引用
收藏
页码：S212 / S212
页数：1
相关论文
共 50 条
  • [31] Patient-reported outcomes with etanercept therapy in patients with plaque psoriasis who lost response to adalimumab
    Papp, Kim A.
    Tyring, Stephen
    Stolshek, Bradley S.
    Rice, Kara Creamer
    Collier, David H.
    Kricorian, Greg
    Iles, Jan
    Kaliyaperumal, Arunan
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB191 - AB191
  • [32] Patient-Reported Outcomes in Patients with Cardiomyopathy
    Raul Angel Garcia
    Mary C. Benton
    John A. Spertus
    Current Cardiology Reports, 2021, 23
  • [33] Patient-Reported Outcomes in Patients with Cardiomyopathy
    Garcia, Raul Angel
    Benton, Mary C.
    Spertus, John A.
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (07)
  • [34] Clinically meaningful improvements in patient-reported outcomes for patients with moderate to severe psoriasis receiving etanercept
    Krueger, G
    Woolley, J
    Zitnik, R
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A55 - A55
  • [35] Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study
    Valenzuela, F.
    Paul, C.
    Mallbris, L.
    Tan, H.
    Papacharalambous, J.
    Valdez, H.
    Mamolo, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (10) : 1753 - 1759
  • [36] Results of patient-reported outcomes from a double-blind study of etanercept and sulphasalazine, alone and combined, in patients with active rheumatoid arthritis
    Singh, A
    Appel, AM
    Kvien, TK
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 355 - 356
  • [37] IMPACT OF ETANERCEPT-METHOTREXATE THERAPY ON PATIENT-REPORTED OUTCOMES IN MODERATELY ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS OF EUROPE, LATIN AMERICA, AND ASIA
    Szekanecz, Z.
    Yen, J. H.
    Miranda, P.
    Szumski, A.
    Bananis, E.
    Kotak, S.
    Rahman, M.
    Tang, B.
    VALUE IN HEALTH, 2012, 15 (07) : A674 - A674
  • [38] Assessment of patient-reported outcomes from a double-blind trial of etanercept and methotrexate combination in early active rheumatoid arthritis: The COMET trial
    Durez, P.
    Emery, P.
    Hall, S.
    Koenig, A.
    Sato, R.
    Singh, A.
    Robertson, D.
    Freundlich, B.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S457 - S457
  • [39] Giant cell arteritis in a patient taking etanercept and methotrexate
    Seton, M
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (07) : 1467 - 1468
  • [40] The effects of weekly etanercept administration on patient-reported outcomes of subjects with rheumatoid arthritis
    Keystone, EC
    Woolley, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 415 - 415
12345